RLF.SW

Relief Therapeutics Holding AG [RLF.SW] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

RLF.SW Stock Summary

Earnings have grown 83.11% per last year.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 24.35%

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Does not have any significance market cap ($13.88M)

Top 10 Correlated ETFs

RLF.SW

Top 10 Correlated Stocks

RLF.SW

In the News

RLF.SW Financial details

Company Rating

Sell

Market Cap

13.88M

Income

-127.32M

Revenue

12.43M

Book val./share

8.52

Cash/share

1.16

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

14 Apr 2024

P/E

-149.84

Forward P/E

PEG

-7.11

P/S

3.26

P/B

52.34

P/C

1.13

P/FCF

-0.8

Quick Ratio

1.8

Current Ratio

2.11

Debt / Equity

0.02

LT Debt / Equity

EPS (TTM)

-12

EPS next Y

EPS next Q

EPS this Y

24.35%

EPS next Y

EPS next 5Y

EPS last 5Y

124.01%

Revenue last 5Y

60.72%

Revenue Q/Q

6.48%

EPS Q/Q

126.67%

SMA20

SMA50

-50%

SMA100

-50%

Inst Own

Inst Trans

ROA

-27%

ROE

-31%

ROC

-0.29%

Gross Margin

-124%

Oper. Margin

-856%

Profit Margin

-835%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.25-15.0

52W High

-91.27%

52W Low

+31%

RSI

Rel Volume

1.72

Avg Volume

15.73K

Volume

27.13K

Perf Week

1.55%

Perf Month

-8.39%

Perf Quarter

-32.82%

Perf Half Y

-37.62%

Beta

-14.37

Volatility

0.03%, 0.07%

Prev Close

3.97%

Price

1.31

Change

7.38%

RLF.SW Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.11	0	0	0.37	0.58
Net income per share	-0.09	-1.42	-1.3	-3.86	-4.8
Operating cash flow per share	-0.12	-0.14	-3.02	-3.98	-2.28
Free cash flow per share	-0.12	-0.14	-3.02	-5.5	-2.33
Cash per share	0.05	0.02	7.18	4.98	1.82
Book value per share	4.15	2.72	11.11	20.21	13.76
Tangible book value per share	-2.72	-1.01	6.01	-2.16	-2.32
Share holders equity per share	4.15	2.72	11.11	20.21	13.76
Interest debt per share	1.07	0.36	0.03	0.26	0.22
Market cap	11.48M	2.1M	649.16M	223.49M	126.84M
Enterprise value	12.27M	3.71M	606M	182.99M	111.95M
P/E ratio	-26.33	-0.28	-82.93	-6.44	-2.5
Price to sales ratio	20.25	0	0	67.3	20.86
POCF ratio	-18.58	-2.81	-35.6	-6.26	-5.26
PFCF ratio	-18.58	-2.81	-35.6	-4.52	-5.15
P/B Ratio	0.54	0.15	9.68	1.23	0.87
PTB ratio	0.54	0.15	9.68	1.23	0.87
EV to sales	21.64	0	0	55.1	18.41
Enterprise value over EBITDA	-25.4	-3.93	-31.4	-5.52	-3.42
EV to operating cash flow	-19.85	-4.97	-33.23	-5.12	-4.64
EV to free cash flow	-19.85	-4.97	-33.23	-3.7	-4.55
Earnings yield	-0.04	-3.55	-0.01	-0.16	-0.4
Free cash flow yield	-0.05	-0.36	-0.03	-0.22	-0.19
Debt to equity	0.25	0.12	0	0.01	0.01
Debt to assets	0.15	0.09	0	0.01	0.01
Net debt to EBITDA	-1.63	-1.7	2.24	1.22	0.46
Current ratio	0.18	0.09	7	2.79	2.11
Interest coverage	-3.47	-6.86	-114.19	-131.38	-186.46
Income quality	1.42	0.1	2.33	1.03	0.47
Dividend Yield	0	0	0.09	0.3	0.05
Payout ratio	0	0	-7.43	-1.95	-0.13
Sales general and administrative to revenue	1.13	0	0	1.7	1.27
Research and developement to revenue	0	0	0	5.73	2.04
Intangibles to total assets	0.99	0.99	0.39	0.8	0.9
Capex to operating cash flow	0	0	0	0.38	0.02
Capex to revenue	0	0	0	-4.13	-0.09
Capex to depreciation	0	0	0	-6.73	-0.13
Stock based compensation to revenue	0.03	0	0	0.34	0.36
Graham number	2.82	9.31	18.01	41.91	38.57
ROIC	-0.02	-0.04	-0.36	-0.19	-0.23
Return on tangible assets	-1.24	-28.37	-0.17	-0.69	-2.69
Graham Net	-2.74	-1.02	5.37	-2.57	-2.11
Working capital	-1.61M	-2.56M	40.16M	35.24M	11.87M
Tangible asset value	-13.94M	-5.3M	36.24M	-19.43M	-24.52M
Net current asset value	-13.94M	-5.3M	35.85M	-15.12M	-20.8M
Invested capital	0.25	0.12	0	0.01	0.01
Average receivables	20.5K	52K	79.5K	1.41M	2.5M
Average payables	306K	201K	857.5K	1.57M	1.66M
Average inventory	-20.5K	-8.5K	0	195.5K	309K
Days sales outstanding	10.94	0	0	301.8	135.35
Days payables outstanding	789.73	103.3K	0	52.11	32.75
Days of inventory on hand	-112.81	0	0	11.99	4.58
Receivables turnover	33.35	0	0	1.21	2.7
Payables turnover	0.46	0	0	7	11.14
Inventory turnover	-3.24	0	0	30.45	79.77
ROE	-0.02	-0.52	-0.12	-0.19	-0.35
Capex per share	0	0	0	-1.53	-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2021-12-31	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.35	0.31	0.26	0.27
Net income per share	-1.76	-2.1	-2.55	-2.25	-5.1
Operating cash flow per share	-2.13	-1.89	-1.42	-0.87	-0.94
Free cash flow per share	-3.77	-1.89	-1.43	-0.91	-0.98
Cash per share	3.05	4.7	2.88	1.79	1.16
Book value per share	14.9	19.07	15.54	13.49	8.52
Tangible book value per share	-2.34	-2.04	-2.69	-2.28	-1.1
Share holders equity per share	14.9	19.07	15.54	13.49	8.52
Interest debt per share	0.99	0.33	0.08	0.2	0.21
Market cap	667.1M	236.9M	136.72M	129.31M	30.59M
Enterprise value	651.88M	196.4M	109.67M	114.42M	22.35M
P/E ratio	-11.36	-2.96	-1.29	-1.33	-0.14
Price to sales ratio	0	71.33	42.17	45.55	10.12
POCF ratio	-37.6	-13.18	-9.29	-13.76	-2.92
PFCF ratio	-21.22	-13.17	-9.21	-13.21	-2.82
P/B Ratio	5.37	1.3	0.85	0.89	0.32
PTB ratio	5.37	1.3	0.85	0.89	0.32
EV to sales	0	59.14	33.83	40.3	7.39
Enterprise value over EBITDA	948.88	-6.07	-5.79	-8.32	-2.25
EV to operating cash flow	-36.74	-10.93	-7.45	-12.18	-2.14
EV to free cash flow	-20.74	-10.92	-7.39	-11.69	-2.06
Earnings yield	-0.02	-0.08	-0.19	-0.19	-1.85
Free cash flow yield	-0.05	-0.08	-0.11	-0.08	-0.35
Debt to equity	0.06	0.01	0	0.01	0.02
Debt to assets	0.04	0.01	0	0.01	0.02
Net debt to EBITDA	-22.15	1.25	1.43	1.08	0.83
Current ratio	1.79	2.79	2.8	2.11	2.3
Interest coverage	-53.97	-17.07	-476.55	-264.05	-130.85
Income quality	1.21	0.9	0.56	0.39	0.19
Dividend Yield	0	0.16	0.04	0.01	0.15
Payout ratio	0	-1.94	-0.18	-0.08	-0.08
Sales general and administrative to revenue	0	0.78	1.22	1.37	1.15
Research and developement to revenue	0	3.37	3.28	0.62	0.31
Intangibles to total assets	0.8	0.8	0.85	0.9	0.85
Capex to operating cash flow	0.77	0	0.01	0.04	0.04
Capex to revenue	0	0	-0.04	-0.14	-0.12
Capex to depreciation	0	-0.01	-0.06	-0.21	-0.22
Stock based compensation to revenue	0	0.28	0.4	0.32	0.17
Graham number	24.29	30.04	29.86	26.16	31.25
ROIC	-0.11	-0.09	-0.12	-0.1	-0.1
Return on tangible assets	-0.41	-0.4	-0.82	-1.29	-2.94
Graham Net	-3.5	-2.42	-2.85	-2.07	-1.52
Working capital	16.24M	35.24M	22.5M	11.87M	9.24M
Tangible asset value	-19.53M	-19.43M	-27.94M	-24.52M	-12.21M
Net current asset value	-18.83M	-15.12M	-25.42M	-20.8M	-15.05M
Invested capital	0.06	0.01	0	0.01	0.02
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	74.42	29.4	71.49	61.57
Days payables outstanding	0	23.79	16.5	15.17	22.37
Days of inventory on hand	0	5.47	2.58	2.12	4.63
Receivables turnover	0	1.21	3.06	1.26	1.46
Payables turnover	0	3.78	5.45	5.93	4.02
Inventory turnover	0	16.45	34.85	42.46	19.43
ROE	-0.12	-0.11	-0.16	-0.17	-0.6
Capex per share	-1.64	0	-0.01	-0.04	-0.03

RLF.SW Frequently Asked Questions

What is Relief Therapeutics Holding AG stock symbol ?

Relief Therapeutics Holding AG is a CH stock and trading under the symbol RLF.SW

What is Relief Therapeutics Holding AG stock quote today ?

Relief Therapeutics Holding AG stock price is $1.31 today.

Is Relief Therapeutics Holding AG stock public?

Yes, Relief Therapeutics Holding AG is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 15.73K
Market Capitalization 13.88M
Employee 69
CEO Ms. Michelle Lock
Headquarters Geneva,CH
IPO Date 2009-08-26
Website https://www.relieftherapeutics.com

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.